Did You Acquire (AQST) Before December 2, 2019? Should Aquestive Therapeutics Management be Held Accountable for Investors Losses? Contact Johnson Fistel
SAN DIEGO, Dec. 18, 2021 (GLOBE NEWSWIRE) — Johnson Fistel, LLP is investigating potential claims on behalf of Aquestive Therapeutics, Inc. (NASDAQ: AQST) against certain of its officers and directors.
Earlier this year, a class action complaint was filed against Aquestive Therapeutics. According to the lawsuit, defendants throughout the Class Period made false and misleading statements and failed to disclose that: (1) data included in the Libervant Buccal Film for the management of seizure clusters (“Libervant”) New Drug Application (“NDA”) submission showed a lower drug exposure level than desired for certain weight groups; (2) the foregoing significantly decreased the Libervant NDA’s approval prospects; (3) as a result, it was foreseeable that the U.S. Food and Drug Administration (“FDA”) would not approve the Libervant NDA in its current form; and (4) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you are a current, long-term shareholder of Aquestive Therapeutics holding shares before December 2, 2019, you may have standing to hold Aquestive Therapeutics from the alleged harm caused by the Company’s officers and directors by making them personally responsible. You may also be able to assist in reforming the Company’s corporate governance to prevent future wrongdoing.
If you are interested in learning more about the investigation, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If emailing, please include a phone number.
Additionally, if you have owned shares since before December 2, 2019, you can [Click here to join this action]. There is no cost or obligation to you.
About Johnson Fistel, LLP:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com. Attorney advertising. Past results do not guarantee future outcomes.
Contact:
Johnson Fistel, LLP
Jim Baker, 619-814-4471
[email protected]
[Click here to join this action]
Disclaimer: This content is distributed by The GlobeNewswire 
